These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25506702)

  • 1. Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions.
    Scribner E; Saut O; Province P; Bag A; Colin T; Fathallah-Shaykh HM
    PLoS One; 2014; 9(12):e115018. PubMed ID: 25506702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of bevacizumab in recurrent glioblastoma.
    Ghiaseddin A; Peters KB
    CNS Oncol; 2015; 4(3):157-69. PubMed ID: 25906439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
    Sinkó D; Nemeskéri C
    Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
    Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
    Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma.
    García-Romero N; Palacín-Aliana I; Madurga R; Carrión-Navarro J; Esteban-Rubio S; Jiménez B; Collazo A; Pérez-Rodríguez F; Ortiz de Mendivil A; Fernández-Carballal C; García-Duque S; Diamantopoulos-Fernández J; Belda-Iniesta C; Prat-Acín R; Sánchez-Gómez P; Calvo E; Ayuso-Sacido A
    BMC Med; 2020 Jun; 18(1):142. PubMed ID: 32564774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment.
    Shen CC; Cheng WY; Lee CH; Dai XJ; Chiao MT; Liang YJ; Hsieh WY; Mao TF; Lin GS; Chen SR; Liu BS; Chen JP
    BMC Cancer; 2020 Jul; 20(1):709. PubMed ID: 32727419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single Cell Mathematical Model Successfully Replicates Key Features of GBM: Go-Or-Grow Is Not Necessary.
    Scribner E; Fathallah-Shaykh HM
    PLoS One; 2017; 12(1):e0169434. PubMed ID: 28046101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASCO 2013: bevacizumab and glioblastoma--a marriage dissolution?
    Addeo R; Perri F; Parlato C; Della Vittoria G
    Curr Med Res Opin; 2014 Sep; 30(9):1871-3. PubMed ID: 24803042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.
    Morisse MC; Etienne-Selloum N; Bello-Roufai D; Blonski M; Taillandier L; Lorgis V; Noël G; Ahle G; Durán-Peña A; Boone M; Chauffert B
    J Neurooncol; 2019 Sep; 144(2):419-426. PubMed ID: 31325146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
    Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
    Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study.
    Motoo N; Hayashi Y; Shimizu A; Ura M; Nishikawa R
    Jpn J Clin Oncol; 2019 Dec; 49(11):1016-1023. PubMed ID: 31665343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab.
    Stecco A; Amatuzzo P; Sponghini AP; Platini F; Quagliozzi M; Buemi F; Guenzi E; Carriero A
    J Neurosurg Sci; 2019 Aug; 63(4):394-401. PubMed ID: 27603407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
    Buie LW; Valgus J
    Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early
    Pasqualetti F; Gonnelli A; Molinari A; Cantarella M; Montrone S; Cristaudo A; Baldaccini D; Mattioni R; Delishaj D; Mazzotti V; Morganti R; Cocuzza P; Fabrini MG; Lombardi G; Rudà R; Soffietti R; Paiar F
    Anticancer Res; 2018 Oct; 38(10):5877-5881. PubMed ID: 30275213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma.
    Hiller-Vallina S; Mondejar-Ruescas L; Caamaño-Moreno M; Cómitre-Mariano B; Alcivar-López D; Sepulveda JM; Hernández-Laín A; Pérez-Núñez Á; Segura-Collar B; Gargini R
    Neuro Oncol; 2024 Jul; 26(7):1213-1227. PubMed ID: 38411438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
    Wang Y; Xing D; Zhao M; Wang J; Yang Y
    PLoS One; 2016; 11(3):e0152170. PubMed ID: 27007828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in recurrent glioblastoma: five informative patient scenarios.
    Mason WP
    Can J Neurol Sci; 2015 May; 42(3):149-56. PubMed ID: 25850429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors.
    Johansen MD; Urup T; Holst CB; Christensen IJ; Grunnet K; Lassen U; Friis S; Poulsen HS
    Cancer Invest; 2018; 36(9-10):512-519. PubMed ID: 30727779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles.
    Sousa F; Dhaliwal HK; Gattacceca F; Sarmento B; Amiji MM
    J Control Release; 2019 Sep; 309():37-47. PubMed ID: 31344424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.